On-chip pharmacology capabilities lend a new approach to discovering therapy-predictive, disease specific and prognostic or pharmacodynamic biomarkers.
Kinase enzymology, substrate identification for novel, mutated or post-translationally modified kinases.
Comparative analysis of your diseases model (in vitro or in vivo and human or rodent) with respect to healthy or wild type counterpart to gain disease specific kinome or signal transduction related information
Discover novel drug targets to guide drug development, where no prior target information is required.
Find the mechanism of action of small molecule or develop (surrogate) PD-markers.
Learn more about this recently published review paper in ‘The current opinion in pharmacology’
Dr. Astrid Weiß, post doc. at the Biomedical Research Center Seltersberg of the Justus-Liebig-University in Giessen, Germany and scientist at the German Center for Lung Research.
Khaled Alganem1, Robert McCullumsmith et al.
www.sciencedirect.com Current Opinion in Pharmacology 2022
Ibrahim AN, Yamashita D, Anderson JC, Abdelrashid M, Alwakeal A et. al.
Scientific Reports | (2022)
Isabel C. Lopez-Mejia, Andree Yeramian et al,
Molecular Oncology 17 (2023)